LaCE (Lactobacillus Paracasei LPB27 On Early Childhood Eczema)

StatusUnknown
PhasePhase 2
Started

Record status This record was last updated June 3, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 2 to 1
    • Start date changed from estimate of Sep 2024 to Nov 15, 2024
    v3
  3. Secondary endpoints: details revised at 1 of 11 entriesv2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The LaCE study is a double-blind, randomised, placebo-controlled trial examining the effectiveness of the probiotic Lactobacillus paracasei LPB27 in treating eczema in young children.
Trial Details
NCT Number NCT06584552
Lead Sponsor The University of New South Wales
Collaborators: Evolution Health Pty Ltd
Conditions
(from sponsor)		 Eczema, Allergy
Related terms Eczema, Hypersensitivity
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov